Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New program aims to boost lung cancer screening through better Doctor-Patient talks

NCT ID NCT07517692

Knowledge-focused Sponsor: University of Massachusetts, Worcester Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 2 times

Summary

This pilot study tests a program called FIX-SDM that helps patients and their primary care providers talk about lung cancer screening. The program gives providers training and materials, and patients receive a smoking history survey, a decision aid, and text messages before their visit. The study will compare this program to usual care to see if it increases the number of people who get screened and improves the quality of the decision-making process.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FIX-SDM program (provider support session, educational materials, patient decision aid, smoking history survey, and text messages)
What this could lead to
If successful, this program could help more people at risk for lung cancer get screened, leading to earlier detection and better outcomes.
What could go wrong
This is a small pilot study with only 120 participants, so results may not apply to everyone. The program may not increase screening rates or be practical for wider use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 120 people

The number the study aims to enrol. It can still change while the study runs.

Started

Apr 2026

Expected to finish

Mar 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

50 to 77 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Primary care provider (PCP) participants: Inclusion criteria * PCPs (physicians or advanced practitioners) * Who practice in general internal medicine or family medicine clinics in UMass Memorial Health * Who care for more than 5 potentially LCS-eligible patients in their practice Exclusion criteria * Participation in the previous study to co-develop the provider intervention (to avoid bias) Patient participants Inclusion Criteria: * Adults between the ages of 50 and 77 * Meets criteria for Lung Cancer Screening (LCS) (Current eligibility includes: An individual who currently smokes or quit smoking within 15 years with at least a 20 pack-year smoking history) * Has a smartphone with texting capability * English-speaking * Has a scheduled PCP visit in the next \~3-6 weeks from study enrollment with one of the PCP participants enrolled in the study Exclusion Criteria: * Prior LCS * Chest CT within the last 12 months * History of lung cancer * Active cancer requiring treatment * Supplemental oxygen use * Pregnancy * Participation in the previous study to co-develop the patient intervention (to avoid bias)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lung cancer screening are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lung cancer screening

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of Massachusetts Chan Medical School

    Worcester, Massachusetts, 01605, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.